PIRS insider filings
PIERIS PHARMACEUTICALS, INC. — 43 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-12-12. Screen PIRS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PIRS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — PIERIS PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-12-12 | 4 | GERAGHTY JAMES A — Director | Disposition to issuer (D): 1 @ $0.01 | EDGAR |
| 2024-12-09 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 500 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | GERAGHTY JAMES A — Director | Purchase (P): 1 @ $1 | EDGAR |
| 2024-08-12 | 4 | ADAR1 Capital Management, LLC — 10% owner ADAR1 Partners, LP — 10% owner | Purchase (P): 3,000 @ $14.89 · Purchase (P): 2,243 @ $15.88 · Purchase (P): 757 @ $15.88 | EDGAR |
| 2023-06-23 | 4 | Barbier Ann — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Said Maya R. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Richman Michael — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Kiener Peter A — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Sherman Matthew L — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-05-30 | 4 | KIRITSY CHRISTOPHER P — Director | Purchase (P): 10,000 @ $0.85 | EDGAR |
| 2023-02-28 | 4 | Bures Thomas — Chief Financial Officer | Grant/award (A): 249,080 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Kaufmann Hitto — Chief Scientific Officer | Grant/award (A): 249,080 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Mousa Ahmed — Chief Business Officer | Grant/award (A): 249,080 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Olwill Shane — Chief Development Officer | Grant/award (A): 249,080 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Yoder Stephen S. — Chief Executive Officer, Director | Grant/award (A): 634,021 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Barbier Ann — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Said Maya R. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Richman Michael — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Kiener Peter A — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Sherman Matthew L — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-05-16 | 4 | Demuth Tim — Chief Medical Officer | Purchase (P): 6,000 @ $1.71 | EDGAR |
| 2022-02-24 | 4 | Demuth Tim — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Mousa Ahmed — Chief Business Officer | Grant/award (A): 215,819 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Olwill Shane — Chief Development Officer | Grant/award (A): 215,819 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Bures Thomas — Chief Financial Officer | Grant/award (A): 215,819 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Kaufmann Hitto — SVP, Chief Scientific Officer | Grant/award (A): 215,819 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Yoder Stephen S. — Chief Executive Officer, Director | Grant/award (A): 625,874 (derivative) @ $0 | EDGAR |
| 2021-09-01 | 4 | Olwill Shane — Chief Development Officer | Option exercise (M): 38,400 @ $1.52 · Sale (S): 9,200 @ $5 · Sale (S): 29,200 @ $5.15 · Option exercise (M): 38,400 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Demuth Tim — Chief Medical Officer | Grant/award (A): 360,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Said Maya R. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Barbier Ann — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Richman Michael — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Kiener Peter A — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Sherman Matthew L — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Bures Thomas — Vice President, Finance | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Kaufmann Hitto — SVP, Chief Scientific Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Yoder Stephen S. — Chief Executive Officer, Director | Grant/award (A): 530,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — PIERIS PHARMACEUTICALS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PIRS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs